Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

The New England Journal of Medicine
Trial to Reduce Alloimmunization to Platelets Study Group

Abstract

We conducted a multi-institutional, randomized, blinded trial to determine whether the use of platelets from which leukocytes had been removed by a filter or that had been treated with ultraviolet B irradiation would prevent the formation of antiplatelet alloantibodies and refractoriness to platelet transfusions. Patients who were receiving induction chemotherapy for acute myeloid leukemia were randomly assigned to receive one of four types of platelets transfusions: unmodified, pooled platelet concentrates from random donors (control); filtered, pooled platelet concentrates from random donors (F-PC); ultraviolet B-irradiated, pooled platelet concentrates from random donors (UVB-PC); or filtered platelets obtained by apheresis from single random donors (F-AP). All patients received transfusions of filtered, leukocyte-reduced red cells. Of 530 patients with no alloantibodies at base line, 13 percent of those in the control group produced lymphocytotoxic antibodies and their thrombocytopenia became refractory to platelet transfusions, as compared with 3 percent in the F-PC group, 5 percent in the UVB-PC group, and 4 percent in the F-AP group (P< or =0.03 for each treated group as compared with the controls; there were no signific...Continue Reading

Associated Clinical Trials

References

Feb 1, 1978·American Journal of Clinical Pathology·P I TerasakiY Iwaki
Sep 1, 1991·The Journal of Clinical Investigation·R KekomakiT J Kunicki
Jan 1, 1971·International Archives of Allergy and Applied Immunology·K Lindahl-Kiessling, J Säfwenberg
Aug 1, 1984·Immunological Reviews·M L Kripke
Jun 1, 1983·American Journal of Hematology·D E HoggeC A Schiffer
Jan 1, 1994·British Journal of Haematology·F NorolN Duédari
Jan 1, 1994·Current Studies in Hematology and Blood Transfusion·G Andreu, J Dewailly
Aug 1, 1996·Transfusion·S MurphyP Rebulla

❮ Previous
Next ❯

Citations

Sep 5, 2002·Journal of Clinical Apheresis·Sabeen AskariJohn Crosson
Apr 20, 2001·Journal of Clinical Apheresis·L T Goodnough
Apr 4, 2001·Indian Journal of Pediatrics·K Janatpour, P Holland
Nov 8, 2002·Indian Journal of Pediatrics·V P Choudhry
Sep 27, 2003·Indian Journal of Pediatrics·K M RadhakrishnanJ Jayaraju
May 8, 2000·Indian Journal of Pediatrics·R Kulkarni, R Gera
Apr 9, 2005·Journal of Thrombosis and Thrombolysis·Hakan OzdoguEbru Kizilkilic
Aug 1, 2007·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·James O ParkWilliam R Jarnagin
Jan 30, 2004·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Daniela PasqualettiGabriella Girelli
Jul 25, 2003·The Journal of Thoracic and Cardiovascular Surgery·John A HawkinsRobert E Shaddy
Jun 9, 2004·Blood Reviews·Joanna Mary Heal, Neil Blumberg
Jul 26, 2003·Transfusion Medicine Reviews·Alan T Tinmouth, John Freedman
Jul 26, 2003·Transfusion Medicine Reviews·Samuel T WorthamBarry Wenz
Dec 20, 1999·Transfusion Medicine Reviews·L A Chambers, J H Herman
Feb 7, 2001·Gastroenterology Clinics of North America·G S MaltzJ L Carson
Mar 21, 2000·Transfusion Science·J B Gorlin
May 15, 2002·Critical Reviews in Oncology/hematology·Richard J Benjamin, Kenneth C Anderson
Nov 15, 2002·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·David H McKennaSoon Park
Sep 28, 2002·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Ralf Karger, Volker Kretschmer
Dec 5, 2012·Bone Marrow Transplantation·B HöchsmannH Schrezenmeier
Jul 4, 2013·Nature Reviews. Clinical Oncology·Charles A Schiffer
Jul 27, 2005·Bone Marrow Transplantation·J M HealN Blumberg
Sep 6, 2000·British Journal of Haematology·L M Williamson
Jun 3, 1999·Transfusion Medicine·D H PamphilonL M Williamson
Nov 13, 2001·Reviews in Clinical and Experimental Hematology·P Rebulla

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.